Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in
pediatric subjects (ages 6 to 11 years old) with plaque psoriasis: